Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lung cancer Follow-Up: is Twice-Yearly CT better than once a year?

NCT ID NCT07581379

Knowledge-focused Sponsor: University of Florida Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows over 1,800 adults who had early-stage lung cancer treatment to see how often they get CT scans and whether scanning every 6 months helps them live longer than yearly scans. Researchers will also check if scan frequency differs by race, income, or location. The goal is to find the best follow-up plan for catching new or returning cancer early.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

1,826 people

The number who actually took part.

Started

Jan 2012

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population includes adults diagnosed with primary, pathologically confirmed stage I-IIIA non-small cell lung cancer (NSCLC) who received curative intent therapy (surgery or SBRT ± adjuvant therapy) within the UF Health system and are captured in the OneFlorida+ data network. Eligible patients must have completed treatment and survived ≥5 months to allow surveillance assessment. Structured EHR, tumor registry data, and unstructured clinical documentation will be used, with NLP applied to classify surveillance vs. symptom-directed imaging and extract clinical, functional, and social determinants of health.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults diagnosed with primary, pathologically confirmed stage I-IIIA non- small cell lung cancer (NSCLC). * Received curative-intent therapy, including: Surgical resection, or Stereotactic body radiation therapy (SBRT), with or without adjuvant therapy. * Completed curative-intent therapy and survived at least 5 months after therapy initiation. * Received care within the University of Florida (Gainesville or Jacksonville) health system, and are included in the OneFlorida+ clinical data network. * Have available: Structured EHR data (including tumor registry linkage, imaging, procedures, and vital statistics), and Unstructured clinical documents (clinic notes, radiology reports, pathology reports) enable NLP extraction. \- Have ≥1 follow-up encounter in the EHR after treatment completion to allow surveillance assessment. Exclusion Criteria: * Histology other than NSCLC, including: Small-cell lung cancer Carcinoid tumors Rare non-NSCLC primary tumors * Metastatic disease (stage IV) at diagnosis. * No curative-intent therapy received (e.g., palliative treatment only). * Patients with incomplete treatment records prevent the determination of the treatment completion date. * Patients with no surveillance-relevant follow-up data, including: No post-treatment clinical notes No radiology/pathology records No linked tumor registry or vital status data * Patients with recurrence or who die within the first 5 months after starting curative-intent therapy (insufficient window for guideline-defined surveillance). * Patients with missing identifiers prevent linkage to cancer registries or the death index. * Individuals whose imaging cannot be classified as surveillance vs. diagnostic due to the absence of relevant structured or unstructured data.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer (diagnosis) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

disease lung cancer lung neoplasm non-small cell lung carcinoma secondary malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer (diagnosis) Lung neoplasms Non-small cell lung cancer (NSCLC), stage I-IIIA Second primary lung cancer (SPLC)

Contacts and locations

Locations

  • University of Florida College of Medicine

    Gainesville, Florida, 32610, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.